References
- Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–1692.
- Juliusson G, Lazarevic V, Hörstedt AS, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–3899.
- Xicoy B, Jiménez MJ, García O, et al. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma. 2014;55(6):1300–1303.
- Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10(3):176–1782.
- Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26(1):98–106.
- Jun HJ, Ko HR, Lee JY, et al. Injection-site reaction following 5-azacitidine injection. Ann Dermatol. 2014;26(5):669–670.
- Shimoda-Komatsu Y, Mizukawa Y, Takayama N, et al. Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: case reports and a lesson from published work review. J Dermatol. 2020;47(4):363–368.
- Banks V, Bale S, Harding K, et al. Evaluation of a new polyurethane foam dressing. J Wound Care. 1997;6(6):266–269.
- O’Meara S, Martyn-St JM. Foam dressings for venous leg ulcers. Cochrane Database Syst Rev. 2013;5:CD009907.
- Jin Y, Li J, Wu S, et al. Comparison of polyurethane foam dressing and hydrocolloid dressing in patients with pressure ulcers: a randomized controlled trial protocol. Medicine (Baltimore). 2021;100(2):e24165.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Pullen RL. Administering medication by the Z-track method. Nursing. 2005;35(7):24.
- Platzbecker U, Aul C, Ehninger G, et al. Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol. 2010;89(4):427–428.
- Blecua P, Martinez-Verbo L, Esteller M. The DNA methylation landscape of hematological malignancies: an update. Mol Oncol. 2020;14(8):1616–1639.
- Plume MA, Sibaud V, Bobin A, et al. Spider-like injection site reaction after subcutaneous administration of haematological treatments. J Eur Acad Dermatol Venereol. 2020;34(3):e142–e144.
- Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130–138.
- Almeida AM, Pierdomenico F. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leuk Res. 2012;36(9):e211–e213.
- Ferruccio LF, Murray C, Yee KW, et al. Tolerability of Vidaza (azacitidine) subcutaneous administration using a maximum volume of 3 mL per injection. J Oncol Pharm Pract. 2016;22(4):605–610.
- Forni C, D’Alessandro F, Gallerani P, et al. Effectiveness of using a new polyurethane foam multi-layer dressing in the sacral area to prevent the onset of pressure ulcer in the elderly with hip fractures: a pragmatic randomised controlled trial. Int Wound J. 2018;15(3):383–390.
- Nair H. Venous leg ulcers managed using polyurethane foam with a micropore dressing: two case reports. J Wound Care. 2018;27(Sup9a):S37–S40.
- Rossi FW, Rivellese F, Napolitano F, et al. Effects of polyurethane foam dressings as an add-on therapy in the management of digital ulcers in scleroderma patients. Transl Med Unisa. 2020;22:10–14.